PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Inclusion Criteria: * 18 years of age or older * Histologically confirmed diagnosis of melanoma or malignant brain tumor at MSKCC * Newly-diagnosed or recurrent (local,regional, metastatic) metastatic melanoma or malignant brain tumor patients with * Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas or malignant brain tumor * Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region. * Newly diagnosed patients with previous excisional biopsy. * Normal baseline cardiac function based upon pre-operative evaluation * At the discretion of the physician ANC\>1000/mcl and platelets\>100,000/mcl. * At the discretion of the physician Bilirubin level of \< 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's). * If patients have a history of malignancy other than melanoma or malignant brain tumor they must be disease-free (excluding primary cancer for metastatic patients) for ≥ 5 years at the time of enrollment. * All patients of childbearing and child-creating age must be using an acceptable form of birth control * Women who are pre-menopausal must have a negative serum pregnancy test Exclusion Criteria: * Abnormal thyroid function, such as untreated clinical diagnosis of hypothyroidism, hyperthyroidism, or other thyroid disease * Known pregnancy or breast-feeding. * Medical illness unrelated to the tumor which in the opin…